Rituximab Maintenance versus Watch and Wait After R-DHAP Followed by ASCT in Young Patients with Previously Untreated MCL


Rituximab Maintenance versus Watch and Wait After R-DHAP Followed by ASCT in Young Patients with Previously Untreated MCL
Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Stephen M Ansell, MD, PhD (1/20/15)
Le Gouill S et al. Rituximab maintenance versus wait and watch after four courses of R-DHAP followed by autologous stem cell transplantation in previously untreated young patients with mantle cell lymphoma: First interim analysis of the phase III prospective LYMA trial, a LYSA study. Proc ASH 2014;Abstract 146.

Dr Ansell is Professor of Medicine in the Division of Hematology at Mayo Clinic in Rochester, Minnesota.